Drug Trial Radar · NCT05456256
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Mar 1, 2023
Primary completion
Dec 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- Lantern Pharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined patient population when LP-300 is co-administered with the standard of care chemotherapy drugs carboplatin and pemetrexed compared to carboplatin and pemetrexed alone. This has been designed as a multicenter, open label, phase II trial with 90 patients to be enrolled in the United States.
Conditions
- Adenocarcinoma of Lung
- Carcinoma, Non-Small-Cell Lung
Interventions
LP-300Drug
LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
PemetrexedDrug
Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion.
CarboplatinDrug
Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Through study completion, an average of 2 years
- Overall survival (OS)Time frame: Through study completion, an average of 2 years
Locations
16 sites in 3 countries. Site status is shown where the registry gives one.
Precision NextGen Oncology and Research Center
Beverly Hills, California · Recruiting
Los Angeles Cancer Network
Fountain Valley, California · Recruiting
Cancer and Blood Specialists Clinic
Los Alamitos, California · Suspended
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
Inova Fairfax Hospital
Fairfax, Virginia · Recruiting
Hokkaido Cancer Center
Sapporo, Hokkaido, Japan · Active not recruiting
Kanagawa Cancer Center Hospital
Yokohama, Kanagawa, Japan · Active not recruiting
Tohoku University Hospital
Sendai, Miyagi, Japan · Active not recruiting
Okayama University Hospital
Okayama, Okayama-ken, Japan · Active not recruiting
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan · Active not recruiting
National Taiwan University Hospital Hsin-Chu Branch
Hsinchu, Taiwan · Recruiting
Chi Mei Medical Center
Tainan, Taiwan · Recruiting
National Cheng Kung University Hospital
Tainan, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
TriService General Hospital-Neihu Main Facility
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.